Atinum Investment

Atinum Investment Co., Ltd., established in 1988 and based in Seoul, is a principal investment firm that focuses on various sectors including information technology, biotechnology, healthcare, renewable energy, and materials science. The firm targets small and mid-sized companies across Asia, aiming to support startups and businesses within the life sciences and related technologies. Atinum Investment's diverse portfolio reflects its commitment to fostering innovation in fields such as communication, media, and distribution, while also emphasizing sustainable practices in its investment approach.

Sung-Hyun Baek

Senior Associate

Kyung Nae Bang

Associate

Kyujin Hwang

Investor

Chang Seok Hwang

Chief Managing Director

Yoon Ho Jung

Associate

Min Su Kang

Senior Associate

Cheuk Kim

Chief Managing Director

Che Uk Kim

Chief Managing Director

Soo Won Kim

Senior Associate

Sang Hoon Kwak

Managing Director

Jaemyung Lee

Investor

SeungYong Lee

CEO

Hyelin Lee

Principal

Seongsik Moon

Senior Associate

Chan Park

Investor

Ki-Chun Shin

CEO / Vice Chairman

Ki Chun Shin

Investor

Past deals in Series E

Fast Five

Series E in 2021
Fast Five operates as a premium office business center, specializing in co-working spaces designed for startups and small-to-medium-sized companies. With a focus on creating an offline social network, Fast Five provides attractive and efficient office environments in high-demand areas without requiring a deposit for leasing. The company emphasizes community building through a dedicated community manager who fosters connections among members, including founders, investors, professionals, and freelancers. In addition to office space, Fast Five offers communal amenities such as free coffee, draft beer, and networking events, enhancing the overall experience for its members while allowing them to avoid the complexities of managing independent office spaces.

RIDI

Series E in 2020
RIDI Corporation is South Korea’s leading e-reading services company, headquartered in Seoul. Eyeing remarkable success for the innovation of reading experiences, the company operates Ridibooks e-book store and provides PAPER PRO. Ridibooks provides the highest quality of reading experience through e-book viewer applications, with a wide selection of e-book contents. The service is available for Ridibooks PAPER PRO (self-developed e-ink reader), iOS, Android, Windows and Mac OS X. Ridibooks now serves more than 2.77 million users and more than 1,620,000 e-book titles until today. PAPER PRO, developed by RIDI Corporation and released in December 2017, is Korea’s first 7.8-inch e-reader. PAPER PRO’s size is optimized for reading, and features an e-ink display that resembles paper books.

RIDI

Series E in 2019
RIDI Corporation is South Korea’s leading e-reading services company, headquartered in Seoul. Eyeing remarkable success for the innovation of reading experiences, the company operates Ridibooks e-book store and provides PAPER PRO. Ridibooks provides the highest quality of reading experience through e-book viewer applications, with a wide selection of e-book contents. The service is available for Ridibooks PAPER PRO (self-developed e-ink reader), iOS, Android, Windows and Mac OS X. Ridibooks now serves more than 2.77 million users and more than 1,620,000 e-book titles until today. PAPER PRO, developed by RIDI Corporation and released in December 2017, is Korea’s first 7.8-inch e-reader. PAPER PRO’s size is optimized for reading, and features an e-ink display that resembles paper books.

Berkeley Lights

Series E in 2018
Berkeley Lights, Inc. is a digital cell biology company based in Emeryville, California, established in 2011. The company focuses on accelerating the development and commercialization of biotherapeutics and other cell-based products through its integrated platform. This platform includes proprietary consumables, such as OptoSelect chips and reagent kits, along with automation systems and workflow software. Utilizing micro-droplet technology, Berkeley Lights offers research and development services that transform how scientists study cell interactions, significantly enhancing the efficiency of cellular therapies. Their solutions cater to various sectors, including biotherapeutic discovery, cellular therapy manufacturing, synthetic biology, and agricultural biotechnology, helping clients meet the increasing demands of cell-based processes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.